Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Drops By 15.7%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 4,250,000 shares, a drop of 15.7% from the January 31st total of 5,040,000 shares. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.5 days.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several hedge funds have recently bought and sold shares of RVPH. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after buying an additional 42,376 shares in the last quarter. EMC Capital Management lifted its position in Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after purchasing an additional 26,134 shares during the period. Drive Wealth Management LLC purchased a new stake in Reviva Pharmaceuticals in the fourth quarter worth approximately $36,000. Ameriprise Financial Inc. bought a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $84,000. Finally, Tang Capital Management LLC purchased a new stake in Reviva Pharmaceuticals during the 4th quarter valued at $308,000. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

RVPH stock traded down $0.05 on Thursday, reaching $1.28. The company’s stock had a trading volume of 53,116 shares, compared to its average volume of 1,801,483. The business has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $1.47. The firm has a market cap of $42.64 million, a PE ratio of -1.15 and a beta of -0.09. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.28.

Wall Street Analyst Weigh In

A number of analysts recently commented on RVPH shares. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. HC Wainwright decreased their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, January 10th. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.